Jimandin (Sitagliptin)

Sitagliptin blocks the enzyme dipeptidyl peptidase‑4 (DPP‑4). This inhibition raises levels of the incretin hormones GLP‑1 and GIP, leading to increased insulin release after meals and reduced glucagon secretion, which together lower blood glucose concentrations.

The appropriate dose of Jimandin is determined by the prescribing healthcare professional based on the individual’s clinical condition, renal function, and response to therapy. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety data for sitagliptin in pregnancy and lactation are limited. The medication should only be used if the potential benefit justifies any possible risk to the fetus or infant, and this decision must be made in consultation with a qualified healthcare provider.

To request Jimandin, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with sulfonylureas, sitagliptin has a lower risk of causing hypoglycemia because its insulin‑stimulating effect is glucose‑dependent. Relative to other DPP‑4 inhibitors, efficacy and safety profiles are broadly similar; the choice often depends on formulation, cost, and patient‑specific factors.

Jimandin tablets should be stored at ambient temperature, below 25 °C, in the original packaging to protect them from moisture and light. Keep the product out of reach of children and do not use after the expiry date.

Jimandin is taken orally, usually once daily, with or without food. The tablet should be swallowed whole with a glass of water. Patients should follow the dosing schedule prescribed by their healthcare professional.

Serious adverse events reported with sitagliptin include acute pancreatitis, severe allergic reactions such as anaphylaxis, and rare bullous skin disorders. Patients should seek immediate medical attention if they experience persistent abdominal pain, rash, or signs of a severe allergic response.

Jimandin is contraindicated in individuals with a known hypersensitivity to sitagliptin or any of its excipients. Caution is also advised for patients with severe renal impairment, uncontrolled heart failure, or a history of pancreatitis, and it should be used only under medical supervision in these groups.